Apremilast in the treatment of moderate to severe hidradenitis suppurativa: A case series of 9 patients
To the Editor: Despite the many therapeutic approaches available for hidradenitis suppurativa, there is still a need for effective medications to treat moderate and severe forms of the disease. In this study, we assessed the efficacy of the oral phosphodiesterase 4 inhibitor apremilast (30 mg, twice a day) in the management of 9 patients with moderate to severe hidradenitis suppurativa (Hurley stage II-III) who had responded poorly to other treatments.
The treatment was assessed using Sartorius score clinical staging, visual analog scale (VAS) for pain, and Dermatology Life Quality Index (DLQI) scores before therapy and 2 to 3 months after induction. Three patients ( patients 7, 8, and 9 in Table I ) failed to continue treatment because of reflux, preexisting depression, and problems with health insurance. Of the remaining 6 patients (mean age, 44.33 6 13.54 years; 5 smokers), 5 showed a promising response, which was shown by a significant improvement in mean 6 standard deviation Sartorius score clinical staging of 73.17 6 67.76 to 56.17 6 44.89 (P ¼ .028; Table I ). A representative patient is shown in Fig 1 (see page 1191) .
Patients reported a mean 6 standard deviation pain VAS score of 7.17 6 0.98 before treatment and 2.00 6 2.10 after therapy, indicating a significant decrease in pain (P ¼ .026). Pain is one of the major symptoms reported by patients with hidradenitis suppurativa and the biggest source of reduced quality of life.
1 This is also shown in the current study by the significant positive correlation between DLQI and VAS pain score in the Spearman correlation coefficient (P ¼ .021, r ¼ 0.655). Most patients added that they were able to cope better with their disease after therapy, as shown by the DLQI, which improved significantly from 21.33 6 8.91 to 9.33 6 5.85 (P ¼ .027).
Although it has many antiinflammatory effects, the mechanism by which apremilast may work in hidradenitis suppurativa is unknown. However, therapy with a phosphodiesterase 4 inhibitor, such as apremilast, which can modulate key pro-and antiinflammatory mediators, such as tumor necrosis factore, interleukin-23 (IL) and IL-12 and chemoattraction via regulation of IL-8 and interferon-einduced protein 10 expression, might suppress the cellular mechanisms involved and expression of many upregulated cytokines in hidradenitis suppurativa. [1] [2] [3] [4] [5] Limitations of this study include its small sample size and short duration. However, the promising results and good tolerability we observed suggest that apremilast may have a role in treatment of moderate to severe hidradenitis suppurativa. We hope that larger, controlled clinical trials will further elucidate the potential role of apremilast for this challenging disease. Trends in indoor tanning and its association with sunburn among US adults To the Editor: Indoor tanning and sunburns increase the risk for skin cancer. 1 We examined trends in indoor tanning among US adults during 2010-2015 and its association with sunburn.
We analyzed data from the 2010, 2013, and 2015 National Health Interview Survey (NHIS), a nationally representative sample of the US civilian noninstitutionalized population aged $18 years. Respondents were asked about indoor tanning and sunburns (from the sun or indoor tanning) during the preceding 12 months. We calculated the prevalence of indoor tanning and examined linear trends using regression analyses. We examined the association between indoor tanning and sunburn in 2015 using multivariable logistic regression and presented results as predictive margins. Parallel analyses were performed among nonHispanic white women aged 18-29 years, the most common users of tanning devices. Annual response rates were 55.2%-61.2%, and sample sizes were 25,233-33,912 persons. Sample weights were applied to account for the complex study design. Data were analyzed using SUDAAN 10.1 (RTI International).
Adult indoor tanning decreased from 5.5% in 2010 to 3.5% in 2015 (P \ .001), from 8.6% to 5.2% (P \ .001) among women, and from 2.2% to 1.6% (P ¼ .004) among men (Table I) . Among nonHispanic white women aged 18-21 years, indoor tanning decreased from 31.8% in 2010 to 20.4% in 2015 (P ¼ .011). In the adjusted model, indoor tanning was positively associated with sunburn; 40.8% of indoor tanners reported at least one sunburn during the preceding year compared with 33.9% of nonindoor tanners (P \ .001) (Fig 1  [see page 1193] ). Among nonHispanic white women aged 18-29 years, 76.9% of indoor tanners reported a sunburn compared with 62.5% of nonindoor tanners (P ¼ .001).
Indoor tanning among US adults has decreased, including among the most common users. In 2015, an estimated 7.8 million adults engaged in indoor tanning, down from 11.7 million in 2010. Increased awareness of risks, 1,2 implementation of a 10% excise tax in 2010, state laws restricting minors' access, 3 new safety measures from the US Food and Drug Administration, 3 and a Call to Action from the US Surgeon General promoting prevention efforts 4 might explain these declines. Indoor tanners were more likely than nonindoor tanners to report sunburns, possibly from tan-seeking behaviors and misperceptions about tanned skin. Persons with tans might overestimate the protection conferred by their tanned skin (or a base tan), possibly leading to additional overexposure to ultraviolet radiation. When asked in 2015 about problems associated with indoor tanning, 6.7% of indoor tanners (an estimated 526,000 adults) reported having been burned by an indoor tanning device in the previous year.
This study is subject to certain limitations. Results from the NHIS are generalizable only to the noninstitutionalized, civilian adult population. In addition, the use of cross-sectional data does not permit a causal inference between indoor tanning and sunburn.
Continued efforts are needed to further reduce indoor tanning. Given continued use among young women and the availability of indoor tanning in unregulated facilities near college campuses, 5 colleges can adopt policies that discourage indoor tanning. Physicians can counsel young adults as recommended by the US Preventive Services Task Force. 4 Reducing indoor tanning remains an important opportunity for the primary prevention of skin cancer. Response to apremilast in patient 2 with gluteal hidradenitis suppurativa. A, Before therapy, erythema, edema, confluent nodules, multiple fistulae, and comedones are present. During therapy, a reduction in erythema, edema, and nodules was observed, though comedones, scars, and hyperpigmentation remained. B, After 2 months of therapy. C, After 8 months of therapy. D, After 9 months of therapy.
